Nereus initiates phase 1b trial of NPI-2358 in NSCLC patients
Nereus Pharmaceuticals, Inc. has begun enrolling patients in an open-label phase 1b study evaluating its vascular disrupting agent NPI-2358 in combination with docetaxel (Taxotere) in patients with non-small-cell lung cancer who previously failed at least one chemotherapy regimen.
SAN DIEGO-Nereus Pharmaceuticals, Inc. has begun enrolling patients in an open-label phase 1b study evaluating its vascular disrupting agent NPI-2358 in combination with docetaxel (Taxotere) in patients with non-small-cell lung cancer who previously failed at least one chemotherapy regimen. NPI-2358 selectively attacks existing tumor blood vessels leading to hemorrhagic tumor necrosis without affecting normal vasculature and it has a direct apoptotic effect on tumor cells.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
